BLB&B Advisors LLC Acquires 2,991 Shares of Danaher Corporation $DHR

BLB&B Advisors LLC lifted its holdings in shares of Danaher Corporation (NYSE:DHR) by 5.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,552 shares of the conglomerate’s stock after buying an additional 2,991 shares during the period. BLB&B Advisors LLC’s holdings in Danaher were worth $11,609,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. WFA of San Diego LLC purchased a new stake in shares of Danaher during the 2nd quarter valued at about $26,000. Howard Hughes Medical Institute bought a new position in Danaher during the second quarter valued at approximately $27,000. TruNorth Capital Management LLC purchased a new stake in Danaher in the third quarter worth approximately $28,000. Red Tortoise LLC boosted its stake in shares of Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after buying an additional 98 shares during the last quarter. Finally, Tripletail Wealth Management LLC bought a new stake in shares of Danaher in the third quarter worth $31,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 3,298 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the sale, the director owned 20,762 shares in the company, valued at approximately $4,702,593. This represents a 13.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares in the company, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 30,248 shares of company stock worth $6,609,663. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $234.91 on Friday. The company has a market capitalization of $165.93 billion, a P/E ratio of 48.43, a P/E/G ratio of 3.58 and a beta of 0.89. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The firm’s 50 day simple moving average is $230.26 and its two-hundred day simple moving average is $213.17. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.5%. Danaher’s dividend payout ratio is currently 26.39%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several research reports. The Goldman Sachs Group raised their target price on Danaher from $265.00 to $270.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 target price (down from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Redburn Partners set a $220.00 price target on shares of Danaher in a research report on Wednesday, October 8th. KeyCorp reiterated an “overweight” rating on shares of Danaher in a research note on Thursday, December 18th. Finally, Morgan Stanley started coverage on shares of Danaher in a research report on Monday, December 1st. They set an “overweight” rating and a $270.00 price objective for the company. Twenty analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $252.09.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.